No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects

Citations Over Time

Abstract

Levothyroxine 300 μg q.d. for 14 days was well tolerated, induced subclinical thyrotoxicosis, and did not affect sorafenib pharmacokinetics. The findings suggest that concomitant use of levothyroxine with sorafenib is not likely responsible for the previously reported increase in sorafenib exposure in patients with DTC. However, the possible effects of long-term levothyroxine dosing were not assessed.

Related Papers

• → Is the treatment of subclinical hypothyroidism beneficial?(2009)14 cited
• Diagnosis and Treatment of Subclinical Hypothyroidism(2006)
• → Levothyroxine Does Not Lower Hypothyroidism Symptoms in Older Adults with Mild Subclinical Hypothyroidism(2017)
• → Levothyroxine for Subclinical Hypothyroidism Does Not Improve Thyroid-Related Symptoms in Patients 80 Years of Age or Older(2019)
• → The efficacy of levothyroxine in the treatment of subclinical hypothyroidism(2013)